Metagenomi Therapeutics, Inc. (NASDAQ: MGX) reported a net loss of $27.482 million for the second quarter ended June 30, 2026, widening from a loss of $19.908 million in the same period last year. Earnings per share came in at $(0.73), missing the analyst consensus estimate of $(0.57) by 28.07 percent. The company’s collaboration revenue collapsed to $(0.257) million, a sharp decline from $8.513 million in Q2 2025, marking a near-total erosion of its top-line performance despite stable research and development spending.

The significant divergence between the revenue collapse and the EPS miss highlights structural cost pressures within the biotech firm. While sales plummeted by over 100 percent year-over-year, operating expenses remained relatively rigid. Research and development (R&D) expenses held steady at $22.512 million, identical to the $22.507 million spent in Q2 2025. General and administrative (G&A) expenses decreased slightly to $6.004 million from $6.993 million in the prior year quarter. This cost structure resulted in a total operating expense of $28.516 million, contributing to an operating loss of $28.773 million.

What the Numbers Show

The financial data reveals that Metagenomi Therapeutics is burning cash at an accelerated rate per unit of equity, even as it curbs some administrative costs. The absolute increase in loss per share from $(0.54) to $(0.73) confirms this trend. However, the company maintains a strong liquidity position to fund its pipeline. As of June 30, 2026, Metagenomi Therapeutics held $120.664 million in cash, cash equivalents, and available-for-sale marketable securities, down from $160.799 million at year-end 2025. Management anticipates this runway will support operations through the fourth quarter of 2027.

Despite the financial headwinds, the company advanced its lead program, MGX-001, for hemophilia A. Two scientific posters received Top Poster Awards at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris, France. One poster highlighted extensive non-human primate preclinical data supporting MGX-001. Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of Metagenomi Therapeutics, stated that the company is engaging with leading hemophilia investigators to establish a foundation for its first-in-human study.

Pipeline and Regulatory Outlook

Metagenomi Therapeutics remains on track to submit an investigational new drug (IND) application in the fourth quarter of 2026 for the global clinical program of MGX-001. IND-enabling studies, including Good Laboratory Practice (GLP) toxicity testing, are expected to be complete by the end of the third quarter of 2026. Subject to regulatory clearance, the company plans to initiate clinical trials in 2027. Additionally, the company continues to evaluate disease indications that have the potential to be treated by protein replacement via gene insertion using its large gene integration system.

Total assets stood at $173.701 million as of June 30, 2026, compared to $221.103 million at December 31, 2025. Total liabilities decreased slightly to $61.134 million from $62.507 million during the same period. The company’s focus remains on disciplined execution toward upcoming regulatory and clinical milestones, leveraging its proprietary CRISPR gene-editing tools to pursue durable genetic medicines.

Chardan Capital analyst Keay Nakae has maintained a Buy rating on Metagenomi Therapeutics while adjusting the valuation outlook. The firm lowered the price target to $5, down from the previous $7.

The revised target reflects an updated assessment of the company's stock potential. Metagenomi Therapeutics is listed on NASDAQ under the ticker symbol MGX.